Trending...
- Beware of Fake City of Spokane Development and Permit Invoices
- Tacoma City Council Adopts 2026 Annual Code Amendments
- Spokane: City Closures Planned for Juneteenth
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
- Joulescope JS320 Launches to Help Engineers Develop Battery-Powered Devices with Greater Confidence
- Ghanaian Afrobeat Artist Praise Kusi Announces Upcoming EP "After 21:00" Releasing July 3, 2026
- TURRENTINE: A Family Legacy United Through Music
- City of Spokane, Spokane Public Schools Partner to Expand Childcare Access
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
0 Comments
Latest on Washingtoner
- Webtronix Designs Web Agency Launches "LocalFind" to Revolutionize AI Local SEO for Local Businesses
- Christmas Miracle Chronicles - New movie coming up this holiday season !
- Healthi Life, Bangkok's Urban Longevity House, Honoured at Asia-Pacific Awards 2025
- ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
- Week 47 Final Freedom Vigil at Alligator Alcatraz: Truth Out
- Psychiatric Hospitals Fail to Warn Electroshock Patients of FDA-Cited Risks in Estimated $7 Billion Industry
- City Asks for Feedback on Design Concepts for Spokane Falls Boulevard
- EasySpanishTax.com Launches Simple DIY Modelo 210 Filing Solution for Non-Resident Property Owners in Spain
- Spokane: New Scam Targeting Families Of Out-Of-Custody Defendants
- Finland Sets Casino Gambling Risk Limits at 2% of Income, 4 Days, 2 Game Types
- Award-Winning Author Diana Colleen Reframes Billionaire-ism, Psychedelic Healing, and the Illusion of Separateness
- The Prolific Writer, Producer "Hunter" Is Bringing New Music For Summer Release
- Millennial Maven Creative Foundation Assists In Bringing Juneteenth to the FIFA World Cup Fan Festival with an Authentically Dallas Lineup
- An AI Memory System Sealed Its Own Records to Bitcoin
- Spokane: DUI Driver Arrested After Vehicle Loses Control and Flips
- Two Florida Family Law Firms Named Among the State's Best Divorce Practices for 2026
- Tacoma: No Impact to Garbage, Recycling and Yard/Food Waste Pick-Ups on June 19
- Tacoma Arts Live And Accelerating Creative Enterprise Present Ace Showace
- George Martinez Launches Community Re-distribution Initiative With Donation to the Gamma Alpha Alpha Chapter of Omega Psi Phi Fraternity, Inc
- SITE Technologies Releases Industry Research Report Exposing the CapEx Intelligence Gap in Commercial Real Estate